AI Article Synopsis
- Uveitis is a common complication in about 23% of ankylosing spondylitis patients, posing significant treatment challenges.
- A 32-year-old male who had recurrent anterior uveitis and inflammatory back pain was eventually diagnosed with ankylosing spondylitis and found clinical remission after starting Golimumab.
- Clinical guidelines support using drugs like etanercept and adalimumab for recurrent uveitis in ankylosing spondylitis, but Golimumab has also shown effectiveness in difficult cases resistant to other treatments.
Article Abstract
Introduction And Importance: Uveitis, as an extra-articular presentation, is found in 23% of patients with ankylosing spondylitis (AS) and is a challenging disease to treat.
Case Presentation: The authors presented a 32-year-old male to the out-hospital, complaining of recurrent anterior uveitis 8 years earlier in his left eye, and suffered from inflammatory lumber pain for 2 years. So a diagnosis of AS after the failure of many therapeutic strategies, 50 mg /month subcutaneous Golimumab was started with clinical remission of AS and uveitis.
Clinical Discussion: The American College of Rheumatology recommends the use of etanercept and adalimumab in the treatment of recurrent uveitis in AS patients. Similarly, the European League Against Rheumatism recommended using Infliximab, Adalimumab, or Certolizumab to prevent the recurrence of uveitis recurrence. Till now, a case about treating refractory uveitis with Golimumab in AS patients was published.
Conclusion: Golimumab was found to be effective in the treatment of uveitis associated with spondyloarthritis refractory at least one immunosuppressive drug.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11305809 | PMC |
| http://dx.doi.org/10.1097/MS9.0000000000002342 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!